- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Gepotidacin vs Nitrofurantoin in uUTI: Study Overview and Clinical Implications
Wendy Cheng, PhD, MPH, discusses how the study on the efficacy of gepotidacin vs nitrofurantoin in a nitrofurantoin-resistant population (a pooled analysis of the EAGLE-2 and EAGLE-3 trials) aimed to evaluate the effectiveness of gepotidacin as a first-in-class oral therapy for uncomplicated urinary tract infections (uUTIs), showing promising results in overcoming antimicrobial resistance and potentially filling critical gaps in current UTI treatments.
EP: 1.Unmet Needs in the Management of UTIs
EP: 2.Gepotidacin vs Nitrofurantoin in uUTI: Study Overview and Clinical Implications
EP: 3.Rethinking Uncomplicated UTI Treatment: Discussion of Aminoglycosides as an Alternative to Carbapenems
EP: 4.Comparing Treatment Options for Acute Pyelonephritis From a Meta-Analysis
EP: 5.Addressing Unmet Needs and Future Outlooks in Treatment of Uncomplicated UTI
Video content above is prompted by the following:
- Briefly describe the study on the efficacy of gepotidacin vs nitrofurantoin in a nitrofurantoin-resistant population: a pooled analysis of the EAGLE-2 and EAGLE-3 randomized controlled trials in uUTI.
- What was the objective of this study?
- How was this study designed? What methodology was used?
- What results were presented?
- Provide your key takeaways from this study. How do the findings contribute to our understanding of uUTIs and antimicrobial resistance, and what role might this first-in-class oral therapy play in addressing current gaps in the treatment landscape?
Infant RSV Hospitalization Rates Drop in First Season With Widespread Preventive Product Use
May 14th 2025New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the importance of timely vaccination and nirsevimab administration.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Bird Flu Risks, Myths, and Prevention Strategies: A Conversation With the NFID's Dr Robert Hopkins
January 21st 2025Joining us for this episode of Managed Care Cast is Robert H. Hopkins Jr, MD, medical director at the National Foundation for Infectious Diseases (NFID), who will help separate fact from fiction about avian influenza and discuss what needs to be done to prevent a future escalation.
Listen
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More
